The economic burden of Medicare-eligible patients by multiple sclerosis type

Value in Health

Volumn 14, Issue 1, 2011, Pages 61-69

  Gilden, Daniel M ^a   Kubisiak, Joanna ^a   Zbrozek, Arthur S ^b,c  

^a JEN Associates Inc   (United States)

^b ASTRAZENECA   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

Chronic progressive multiple; Economic burden; Health care economics; Medical care costs; Medicare; Multiple sclerosis; Relapsing remitting multiple; Sclerosis

Indexed keywords

ADULT; AGED; ARTICLE; CLASSIFICATION ALGORITHM; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIPLE SCLEROSIS; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; UNITED STATES; COMPARATIVE STUDY; ECONOMICS; HEALTH STATUS; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; STATISTICAL MODEL; UTILIZATION REVIEW;

ADULT; AGED; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH STATUS; HUMANS; MALE; MEDICARE; MIDDLE AGED; MODELS, ECONOMETRIC; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; UNITED STATES;

EID: 79952691536     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.022     Document Type: Article

References (25)

1. Multiple Sclerosis International Federation. Atlas of MS Database. London, UK. Available from: http://www.atlasofms.org/index.aspx [Accessed May 27, 2010].
2. Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the "common" neurologic disorders? Neurology 2007;68:326-37. (Pubitemid 46188246)
3. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52. (Pubitemid 46824250)
4. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002;8:469-76.
5. Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002;58:37-43. (Pubitemid 34041935)
6. Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 2010;28:363-79.
7. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51.
8. Pachner AR, Steiner I. The multiple sclerosis severity score (MSSS) predicts disease severity over time. J Neurol Sci 2009;278:66-70.
9. Grudzinski AN, Hakim Z, Cox ER, Bootman JL. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. Pharmacoeconomics 1999;15:229-40. (Pubitemid 29133460)
10. Trisolini M, Honeycutt A, Wiener J, Lesesne S. Global economic impact of multiple sclerosis. Multiple Sclerosis International Federation. London, UK. Available from: http://www.msif.org/document.rm?id=650 [Accessed May 27, 2010].
11. Kobelt G, Berg J, Atherley D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-1702. (Pubitemid 43964625)
12. Kobelt G, Berg J, Atherley D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. Working Paper Series in Economics and Finance, 594, Stockholm School of Economics, 2005. Available from: http://ideas.repec.org/p/hhs/hastef/0594.html [Accessed May 27, 2010].
13. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25. (Pubitemid 28515352)
14. Bloom BS, Bruno DJ, Maman DY, et al. Usefulness of US costof-illness studies in healthcare decision making. Pharmacoeconomics 2001;19:207-13. (Pubitemid 32176473)
15. Marrie RA, Cutter G, Tyry T, et al. Changes in the ascertainment of multiple sclerosis. Neurology 2005;65:1066-70. (Pubitemid 41429632)
16. Bratesman S, Saucier P, Muskie School of Public Service, University of Southern Maine. Applying managed fee-forservice delivery models to improve care for dually eligible beneficiaries. MMIP Technical Assistance Paper No. 12. University of Maryland Center on Aging, Medicare/Medicaid Integration Program, May 2002. Available from: http://www.gmu.edu/centers/chpre/research/MMIP/ TApapers/TA12.pdf [Accessed May 28, 2010].
17. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 2004;83:25-32. (Pubitemid 38141890)
18. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 2006;7(Suppl. 2):S5-13.
19. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17.
20. Fleming ST, Blake Jr RL. Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol 1994;47:1127-32. (Pubitemid 24322808)
21. Redelings MD, McCoy L, Sorvillo F. Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001. Neuroepidemiology 2006;26:102-7. (Pubitemid 43201305)
22. Marrie R, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008;14:1091-8.
23. Marrie RA, Horwitz R, Cutter G, et al. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Neurology 2009;72:117-24.
24. Kang JH, Chen YH, Lin HC. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol 2010;17:1215.
25. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041-7.